Skip to main content

Raltegravir clinical efficacy against B subtype and non-B subtype HIV-1 is similar

Purpose of the study

Raltegravir (RAL) is the first approved HIV integrase inhibitor and has demonstrated potent efficacy in both treatment-experienced and -naïve HIV-infected patients (pts). This analysis reports long-term efficacy data from one Phase II and two Phase III studies in pts infected with non-B subtype virus.

Methods

Each study was double-blind and randomized; all pts received a background ART regimen (see table in Figure 1). Primary results have been presented for each study. Protocol (P) 004 in treatment-naïve pts was a dose-ranging study of RAL vs. efavirenz (EFV) until week 48 after which all pts in RAL groups received 400 mg BID. BENCHMRK-1 and -2 were identical Phase III studies using RAL at 400 mg BID vs. placebo (PBO) in highly treatment-experienced pts with multi-drug resistant virus failing other therapies. Each of the three studies showed potent clinical efficacy for RAL-treated pts. In this analysis, P004 results are shown for all RAL dose groups combined at week 96, and BENCHMRK-1 and -2 results are shown combined at week 48. Non-B subtypes were combined for the analyses due to small numbers of each specific non-B subtype.

Figure 1
figure 1

Percent of pts with HIV RNA <50 copies/ml.

Summary of results

In total, 622 pts were randomized to RAL and 275 to comparator across the three studies. Non-B subtype virus was isolated at baseline in 62 pts in the RAL groups (23 from P004), and in 23 pts in the comparator groups (8 from P004). Subtypes AE and D were most common, isolated in 40 and eight pts, respectively. Data are available for 58/62 and 22/23 of pts with non-B subtype virus using the observed failure approach for % with RNA < 50 copies/mL (see table in Figure 1). RAL-treated pts demonstrated increases from baseline in CD4 of 216 and 250 cells/mm3 for B and non-B, respectively, at week 96 in P004, and of 105 and 150 cells/mm3, for B and non-B, respectively, at week 48 in BENCHMRK-1 and -2.

Conclusion

In these studies, RAL showed similar and potent clinical efficacy in patients with B subtype and non-B subtype HIV in both treatment-naïve and treatment-experienced populations.

Author information

Authors and Affiliations

Authors

Rights and permissions

Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://creativecommons.org/licenses/by-nc/2.0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Reprints and Permissions

About this article

Cite this article

Teppler, H., Rockstroh, J., Isaacs, R. et al. Raltegravir clinical efficacy against B subtype and non-B subtype HIV-1 is similar. JIAS 11, P207 (2008). https://doi.org/10.1186/1758-2652-11-S1-P207

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1758-2652-11-S1-P207

Keywords

  • Efavirenz
  • Raltegravir
  • Integrase Inhibitor
  • Identical Phase
  • P004 Result